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The transcription factor PAX5 is an essential master regulator of B cell development. It is expressed  exclusively  in  the  B‐lymphoid  lineage  of  the  hematopoietic  system  and  is required  for  progression  beyond  the  pro‐B  cell  stage.  Pax5  fullfills  a  dual  role  by repressing  B‐lineage‐‘inaproppriate’  genes  and  simultaneousy  activating  B  cell‐specific genes (Cobaleda et al., 2007). Pax5 is known to play an oncogenic role in a subset of B‐cell non‐Hodgkin’s  lymphoma where  its  intact  sequence  is  brought  under  control  of  strong enhancers or promoters from the IGH locus. Recently, Pax5 was reported to be a frequent target  of  somatic  mutations  in  pediatric  acute  lymphoblastic  leukemia  (ALL),  being altered in more than 30% of the examined cases (Mullighan et al., 2007). Moreover, Pax5 is  a  reported  target  of  different  chromosomal  translocations  in  ALL  resulting  in  fusion genes  encoding  chimeric  proteins  with  novel  functions.  One  of  them  is  the  dicentric translocation  (9;12)(p13;p13)  resulting  in  the  fusion  of  Pax5  to  the  transcriptional repressor gene Etv6. This was one of the first Pax5 fusions in ALL to be reported and is a recurrent chromosome abnormality that accounts for close to 1% of childhood ALL. The resulting  fusion protein  is  comprised of  the  entire DNA‐binding paired domain of  Pax5 fused to the nearly intact sequence of Etv6 with its DNA‐ and protein‐interacting domains. The translocation affects only one allele of Pax5  leaving the second one intact. However, there  is no apparent explanation  for  the cause of  leukemogenesis since  it  is known that heterozygous Pax5+/­ mice have no apparent defects in B cell development (Urbanek et al., 1994; Nutt et al., 1999). This fact paves the way for the hypothesis that the fusion product resulting  from  the  translocation must  act  as  a  negative  regulator  to  interfere  with  the function of remaining wild type Pax5 protein. Recent in vitro transient transfection assays of PAX5‐ETV6 in cultured pro‐B cells have supported this hypothesis.  To  investigate  the  functions  of  PAX5‐ETV6  fusion  protein  leading  to  leukemogenesis  I established  in  vivo  mouse  model  by  generating  a  conditional  Pax5­Etv6  translocation allele. The analysis of this mouse model  is  likely to provide novel  important insight into the role of Pax5 in ALL development. 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Zusammenfassung 
Der  Transkriptionsfaktor  PAX5  ist  ein  essentieller  Regulator  der  B  Zellentwicklung.  Während der Hämatopoiese wird  er  ausschließlich  in  der B‐Zellentwicklung  exprimiert und  ist  für  deren  Weiterentwicklung  ab  dem  pro‐B‐Zell  Stadium  notwendig.    Auf  der molekularen  Ebene  spielt  Pax5  eine  Doppelrolle:  die  B‐Zellspezifischen  Gene  werden hochreguliert und die B‐Zellunspezifischen gleichzeitig reprimiert (Cobaleda et al., 2007).    Es ist bekannt, dass Pax5 als Onkogen an der Entstehung von B‐Zelltumoren beteiligt sein kann, wie  z.B  in manchen Non‐Hodgkin  Lymphomen, wo die  intakte  Sequenz  von Pax5 unter  die  Kontrolle  von  starken  Enhancern  oder  Promoteren  des  IGH  Lokus  gebracht wird.  Vor  kurzem wurde  festgestellt,  dass Pax5  das  am  häufigsten mutierte  Gen  in  der akuten  lymphoblastischen  B‐Zellleukämie  (B‐ALL)  ist.  Es  ist  in  mehr  als  30%  der analysierten  Krankheitsfälle  von  somatischen  Mutationen  betroffen  (Mullighan  et  al., 2007). Ein Teil dieser Leukämien enthalten Translokationen, die zur Bildung von neuen chimären Proteinen mittels Fusion der N‐terminalen DNS‐bindenden Domäne von Pax5 an C‐terminale Sequenzen verschiedener Partnerproteine führen. Möglicherweise weisen diese  auch  neuartige  Funktionen  auf.  Eine  dieser  Anomalien  ist  die  dizentrische (9;12)(p13;p13) Translokation, die zur Fusion von Pax5 an den Transkriptionsrepressor 
Etv6  führt. Diese war  eine der  ersten berichteten Translokationen der B‐ALL und  ist  in ungefähr 1 % aller B‐ALL Fälle zu finden. Das entstandene Fusionsprotein beinhaltet die ganze  DNS‐bindende  paired  Domäne  von  Pax5,  die  mit  der  fast  ganzen  Etv6  Sequenz fusioniert ist, sowie mit ihren unberührten Protein‐ und DNS‐bindenden Domänen. Diese Translokation betrifft nur ein Pax5 Allel, das zweite bleibt intakt. Da aber bekannt ist, dass 
Pax5+/­ heterozygote Mäuse keine Defekte  in der B‐Zellentwicklung aufweisen  (Urbanek et  al.,  1994;  Nutt  et  al.,  1999),  gibt  es  keine  offensichtliche  Erklärung  für  die Läukemogenese.  Diese  Tatsache  lässt  die  Hypothese  zu,  dass  das  aus  der  erwähnten Translokation  entstehende  Fusionsprodukt  als  ein  negativer  Regulator  agieren müsste, um auf diese Weise die normale Funktion des Wildtyp Pax5 zu beeinflussen.  Vor  kurzem  durchgeführte  in  vitro  transiente  Transfektionsassays  in  PAX5‐ETV6  B‐Zellkulturen haben diese Theorie unterstützt. 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The cells of the immune system originate in the bone marrow, where many of them also mature. They then migrate to guard the peripheral tissues, circulating in the blood and in a  specialized  system of vessels  called  the  lymphatic  system. All  the  cellular  elements of blood, including the red blood cells that transport oxygen, the platelets that trigger blood clotting  in  damaged  tissues,  and  the  white  blood  cells  of  the  immune  system,  derive ultimately  from  the  same progenitor  or  precursor  cells  ‐  the  pluripotent  hematopoietic stem cells which  reside  in  the bone marrow  (Figure 1).    Initially  they  give  rise  to  stem cells of more limited potential, the common myeloid progenitors (CMPs) and the common lymphoid progenitors (CLPs). The CMP is the immediate precursor of the oxygen carrying red  blood  cells  and  platelets  but  will  also  give  rise  to  granulocytes,  macrophages, dendritic  cells,  and  mast  cells  of  the  immune  system.  The  CLP  gives  rise  to  the lymphocytes  and  natural  killer  cells.  There  are  two  major  types  of  lymphocyte:  B lymphocyte  or  B  cell, which mature  in  the  bone marrow  and  T  lymphocytes  or  T  cells which  mature  in  the  thymus.  Each  individual  lymphocyte  matures  bearing  a  unique variant of a prototype antigen receptor and is able to mount a specific immune response against virtually any foreign antigen, a molecule, which will bind the lymphocyte receptor.  The  B  and  T  lymphocytes  collectively  bear  a  huge  repertoire  of  receptor molecules  on their  surface  that  are  highly  diverse  in  their  antigen  binding  sites.  Adaptive  immune responses are initiated in the peripheral lymphoid tissues such as spleen, lymph nodes or mucosal  associated  lymphoid  tissues.  T  cells  that  encounter  antigen  proliferate  and differentiate  into  antigen  specific  effector  cells  capable  of  killing  cells  infected  with viruses, while B cells proliferate and differentiate into antibody secreting cells. Antibodies are the secreted form of the B‐cell antigen receptor (BCR). The stepwise expression and assembly of components of the functional receptor for antigen is the hallmark of early B cell development.  An antibody molecule also known as  immunoglobulin (Ig) molecule  is composed of  two distinct  regions.  One  is  the  constant  region  that  can  take  one  of  only  four  or  five 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Hematopoietic  stem  cells  develop  into  B  cells  by  first  generating  lymphoid  primed multipotent  progenitors,  which  subsequently  differentiate  via  the  earliest  lymphocyte progenitor cell stage to common lymphoid progenitors (CLPs) with their characteristic B, T and natural killer cell potential (Busslinger, 2004). B cell  lymphopoiesis  is  initiated by the  entry  of  progenitors  into  the  B‐cell  lineage  transcription  programme  and  the concomitant  sequential  rearrangement  of  the  immunoglobulin  genes  through  VH‐DJH recombination (Fuxa and Skok, 2007).    Entry of CLPs into the B cell lineage depends on three transcription factors:  a basic helix‐loop‐helix protein E2A, the early B cell factor EBF1 and Pax5, also known as B‐cell specific  activator protein BSAP,  one of  nine paired box  family  transcription  factors  and the  only  one  of  them  expressed  within  the  mammalian  hematopoietic  system.  B‐cell development  is  blocked  at  its  earliest  stages  in  the  absence  of  any  one  of  these transcriptional  regulators  (Cobaleda  et  al.,  2007).  E2A  and  EBF1  activate  B‐lymphoid genes  thus  acting  as  lineage  specification  factors.  Pax5  controls  the  commitment  of lymphoid progenitors  to  the B‐cell  lineage.   Pax5‐deficient pro‐B cells  are uncommitted progenitors and have the potential to develop into various other hematopoietic cell types except  for  B‐cells,  which  can  only  develop  upon  the  reactivation  of  Pax5  expression, which restricts the developmental potential of progenitor cells to the B cell pathway (Nutt et al., 1999). At the molecular level Pax5 has a dual function. During B cell commitment it represses  the  transcription  of  B‐lineage  inappropriate  genes  (Delogu  et  al.,  2006)  and simultaneously  activates  the  expression of B  cell‐specific  genes  (Schebasta  et  al.,  2007) thus restricting the broad signaling capacity of B cell‐ progenitors to the B cell pathway (Figure 2), inducing VH‐DJH recombination, enabling (pre) B cell receptor signaling as well as regulating adhesion and migration that way promoting the development towards the mature B cell stage (Delogu et al., 2007; Schebesta et al., 2007).   Chromatin profiling by ChIP on‐chip analysis has shown that Pax5 directly activates the  chromatin  at  promoters  or  putative  enhancers  of  its  target  genes  (Schebasta  et  al., 2007). Pax5 is continuously and exclusively expressed in the B lymphoid lineage beginning at the committed pro B cell stage to the mature B cell stage where its continuous expression is 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required for the maintenance of the B cell identity and function (Horcher et al. 2001; Fuxa and  Busslinger,  2007).  Its  expression  is  subsequently  repressed  during  the  terminal plasma cell differentiation (Fuxa and Busslinger, 2007). Surprisingly,  conditional  Pax5  deletion  allows  mature  B  cells  from  peripheral lymphoid organs to dedifferentiate in vivo back to early uncommitted progenitors in the bone marrow, which are subsequently able to develop into T cells. Hence the loss of Pax5 can  induce  the  conversion  of  mature  B  lymphocytes  into  functional  T  cells  via dedifferentiation to uncommitted progenitor cells (Cobaleda et al., 2007). Together these studies have identified Pax5 as a crucial guardian of B lymphocyte identity and function (Cobaleda et al., 2007).  
   
Figure 2.  The dual role of Pax5 during B lineage commitment. 
Pax5  activates  B  cell  specific  genes  (e.g.  CD19,  CD22  and  mb­1)  and  simultaneously  represses  lineage­
inappropriate genes at B cell commitment. The latter are essential for diverse cellular functions such as cell–




The  central  feature  of  paired  box  transcription  factors  is  the  highly  conserved  DNA‐binding  region  of  about  128  amino  acids,    the  paired  domain  (Figure  3.),  which  was originally  described  in  the  Drosophila  protein  paired  (Underhill,  2000).  This  domain consists of  two homeodomain  like helix‐turn‐helix   subdomains,  the N‐terminal PAI and the  C  terminal  RED  domain  (Breitling  and  Gerber,  2000),  each  with  distinct  sequence recognition properties (Czerny et al. 1993), which enable them to bind a distinct half‐site of the Pax5 recognition sequence in adjacent major grooves of the DNA helix (Garvie et al. 2001). Both subdomains can bind DNA independently (Czerny et al. 1993, Epstein et al. 1994,  Vogan  et  al.  1996,  Kozmik  et  al.  1997).  The  paired  domain  has  retained  a  high degree of homology between mouse and humans (Ghia et al., 1998). Pax5 also contains an amino terminal remnant of a homeodomain (Dahl et al. 1997), as well as a protein‐protein interacting octapeptide motif (Eberhard et al. 2000), that is conserved in all Pax proteins with  the  exception  of  Pax4  and  Pax6.  The  C  terminal  protein  interaction  motifs  are responsible  for  the  repression  and  activation  functions  of  Pax5  (Cobaleda  et  al.,  2007; Dörfler und Busslinger, 1996; Eberhard und Busslinger, 1999).  
  
Figure 3. Schematic representation of Pax5 (Maier, Hagman 2002)  




Over the past years there has been a lot of evidence for the involvement of Pax5 in specific chromosomal  translocations,  which  have  lead  to  its  oncogenic  activation  and consequently  to malignancies of hematopoietic origin.  One example is the misguided class switch recombination responsible for the generation of the t(9;14)(p13;q32) translocation, which leads to the deregulation of Pax5 expression in non‐Hodgkin lymphoma.    In  this  recurrent  translocation  t(9;14)(p13;q32),  Pax5  gene  sequence  of chromosome 9p13 is inverted and juxtaposed to the constant gene region of the IGH  gene locus (Busslinger et al., 1996; Iida et al., 1996; Morrison et al., 1998). The transcription of the  structurally  intact  PAX5  gene  is  deregulated  by  insertion  of  the  potent  IGH  Eµ enhancer or an antisense IGH Sµ promoter (Iida et al., 1996; Morrison et al., 1998; Sonoki et al., 2004) (Figure 4).     
 
 
Figure  4.  Structure  of  the  regulatory  IGH­PAX5  translocation.  Transcription  of  the  structurally  intact  PAX5 
gene is deregulated in two different ways by the t(9;14)(p13;q32) translocation in human B cell non­Hodgkin 
lymphoma. Top, in the KIS­1 translocation, by insertion of the potent IGH Eµ enhancer (Busslinger et al., 1996). 
Top, by insertion of an antisense IGH Sµ promoter (Iida et al., 1996; Morrisson et al., 1998).   Another example for the Pax5 involvement in malignant chromosomal translocations are the  recently  reported  cases  of  specific  chromosomal  translocations  in  pediatric  B  cell precursor acute  lymphoblastic  leukemia (BCP‐ALL) patients, which  lead to  the  fusion of 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the  N  terminal  part  of    Pax5  to  the  C  terminal  sequences  of  different  fusion  partner proteins this way generating novel transcription factors (Nebral et al., 2008).  The first translocation to be described was Pax5 and Etv6 (Carroll et al., 1987; Cazzaniga et  al.,  2001;  Strehl  et  al.,  2003).  Subsequently  eleven  additional  translocations  were identified; PAX5­FOXP1, PAX5­ZNF521, PAX5­PML1, PAX5­ELN, PAX5­DACH1, PAX5­BRD1, 
PAX5­POM121,  PAX5­HIPK1,  PAX5­JAK2,  PAX5­AUTS2  and  PAX5­C20orf112  (see  Table  1, Figure  5).    These  translocations  fused  Pax5  to  six  different  transcription  factors  (Etv6, Foxp1,  Znf521,  Pml,  Dach1  and  Brd1),  two  kinases  (Hipk1  and  Jak2),  two  structural proteins (Pom121 and Elastin) as well as two proteins of unknown function (Auts2 and C20orf112).  In most  BCP‐ALL  cases  analyzed,  these  translocations were  unbalanced  as the  reciprocal  translocation  could  not  be  detected  (Cazzaniga  et  al.,  2001;  Strehl  et  al., 2003; Nebral et al., 2008; Kawamata et al., 2008; An et al., 2008).    
  









The  short  arm of  chromosome 12 has been  long known as a hot  spot  for  chromosomal rearrangements  in  diverse  types  of  leukemias  and  myelodysplastic  syndromes (Bohlander,  2005).  These  rearrangements  include  balanced  translocations with  a  great number of different chromosome partner bands as well as unbalanced translocations and deletions, which have led to the loss of genetic material from 12p. Molecular cytogenetic studies showed that more than half the observed balanced translocations had breakpoints that  were  clustered  in  a  single  yeast  artificial  chromosome  clone  located  at  12p13 (Kobayashi et al., 1994). More than 40 translocations with ETV6 involvement have been reported (Odero et al., 2001). In  1994,  Todd  Golub  in  Gary  Gillilands  group  succeeded  in  cloning  the ETV6/PDGFRB  fusion  gene,  which  was  the  result  of  a  balanced  t(5;12)(q31:p13) translocation  that  had  been  found  in  malignant  cells  from  a  patient  with  chronic myelomonocytic leukemia (CMML) a myelodysplastic syndrome which is characterized by progression to  acute myeloid leukemia (AML) (Golub et al., 1994). They found a fusion of the  platelet  derived  growth  factor  receptor  beta  gene  located  at  band  5q31  that  was known already at the time to a previously unknown gene from chromosome 12 band p13, which  they  called  TEL  (Translocation  Ets  Leukemia  gene).  TEL  was  later  renamed  to ETV6 (ets variant gene 6) by  the nomenclature commission  in order  to avoid confusion with the abbreviation for telomere. ETV6  is  a member of  the ets  (E‐26  transforming  specific)  family of  transcription factors. All ets family proteins share a very conserved protein domain of about 88 amino acids in length the so‐called ets domain (Bohlander, 2005) (Figure 6). The Ets domain is a sequence‐specific DNA‐binding domain but it also mediates protein‐protein  interaction,  it  is evolutionarily highly conserved and found also  in  invertebrates such  as  Drosophila  and  C.elegans  (Oikawa  and  Yamada,  2003;  Wasylyk  et  al.,  1993). Interestingly,  the  ets  domain  of  ETV6  is  more  closely  related  to  the  ets  domain  of  the 
Drosophila  protein yan  than  to  the ets  domain of  the human ETS1  or SPI1  (PU.1)  genes (Golub et al., 1994). The other evolutionarily conserved domain in the 652 amino acids of Etv6 is the N‐terminally  located pointed or sterile alpha motif  (SAM) domain whose 3D structure has 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recently been elucidated (Tran et al., 2002; Kim et al., 2001). This domain, also known as HLH  domain  is  even  more  highly  conserved  in  evolution  and  can  be  found  in  many different ets family members (Bohlander, 2005). It is found in yeast proteins and has been shown  to  be  involved  in  homo‐  and  heterodimerization  of  transcription  factors  and  in signal  transducing  proteins  (e.g.  of  the  MAPK  pathway)  (Grimshaw  et  al.,  2004).  Etv6 contains two alternative translation start codons at positions 1 and 43, which lead to the expression of two isoforms of the transcription factor (Bohlander, 2005). ETV6 has been  found  fused  to many different partners,  some of  them prominent players in leukemogenesis such as RUNX1 and ABl1 (Golub et al., 1995; Golub et al., 1996; Papadopoulos  et  al.,  1995)  (Figure  7).  The  different  types  of  fusion  partners  include protein tyrosine kinases as well as transcription factors. A number of fusions do not seem to lead to meaningful fusion proteins and are therefore regarded as “unproductive”.   
  
Figure 6. ETV6: a  schematic  representation.   The PAX5  fusion breakpoint  located  in  intron 2 of Etv6 at  the 







 B‐cell  precursor  Acute  Lymphoblastic  Leukemia  (BCP‐ALL)  belongs  to  the  family  of genetically  heterogeneous  lymphoid  neoplasms  derived  from  B‐lymphoid  progenitors and is the main type of childhood leukemia with a marked age incidence peak at 2‐5 years (Greaves  ans Wiemels,  2003).  It  has  a B‐cell  precursor phenotype;  'Acute'  refers  to  the undifferentiated,  immature  state  of  the  circulating  lymphocytes  ("blasts"),  and  to  the rapid progression of the disease, during which lymphoblasts uncontrollably multiply and are overproduced in the bone marrow, outcrowding other cells present and as a result of this can produce  lymphocytosis, spread to other organs and form metastases which can be fatal in weeks to months if left untreated.  As with  the other  acute  leukemias,  the most  common  symptoms  experienced by patients include fatigue, bleeding, and recurrent infections resulting from the suppression of  normal  hematopoiesis  in  the  bone  marrow  by  the  accumulating  blasts  (Randolph, 2004). ALL exhibits  the best  response  to  standard  chemotherapy as  compared  to  acute myeloblastic leukemias (AML). Further, remission rates are highest among ALL patients, many of whom are experiencing sustained remissions suggesting cure.  Although  advances  in  treatment have  led  to  an overall  favourable  outcome with  a  cure rate of~80%, some subtypes of leukaemia still remain unresponsive to therapy (Greaves ans  Wiemels,  2003).  Approximately  25%  of  the  patients  suffer  from  relapse,  which diminishes the chances of complete cure considerably (Pui et al., 2004). 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1.7 Subtypes of BCP‐ALL 
In  light  of  early  treatment  successes,  researchers  began  to  investigate modifications  of standard treatment regimens to accommodate variability in weight, age, and response to therapy  among  children  with  ALL.  Individualized  treatment  plans  were  implemented where  some  patients  received  a  reduced  intensity  course  of  therapy  to minimize  drug toxicity while others received drug intensification to maximize response.  More  recently,  research  efforts  have  been  directed  at  the  elucidation  of  leukemogenic mechanisms  implicated  in  ALL  to  identify  specific  protein mutants  that  can  be  used  to design  drugs  tailored  to  interfere  with  the  activity  of  these  mutant  protein  targets. Identification of chimeric proteins produced from chromosomal translocations and gene expression profiles from microarray analyses are the primary techniques used to identify the potential therapeutic targets.  The main  subtypes  of  BCP‐ALL  involve  a  large  variety  of  genetic  alterations,  including point mutations and cryptic deletions, but  they are characterized by gross chromosome changes such as hyperdiploidy (in ~35% of BCP‐ALL cases) leading to an increased gene dosage  or  translocations,  the  latter  seem  to  arise  mainly  before  birth  at  the  level  of hematopoietic stem cells during fetal hematopoiesis (Greaves and Wiemels, 2003).   Chromosome  translocations,  mostly  caused  by  double‐strand  DNA  breaks  involve illegitimate  recombination  or  juxtapositioning  of  normally  separate  genes  to  active regulatory elements as  in  case of MYC with  the  Immunoglobulin Heavy Chain  (Rabbitts 1994, 1993).   However, more  commonly  in  leukemia  an  in‐frame  chimeric  or  fusion  gene  is  created, generating a hybrid protein with altered properties ‐ usually resulting in activated kinase activity or novel transcriptional regulation (Look, 1997; Rowley, 1998) (Tables 1 and 2).  
  22 
  Chromosome abnormality  Molecular lesion  Frequency (%)  Functional Product t(12;21)(p13;q22)  TEL (ETV6)‐AML1fusion  ~ 20 in BCP‐ ALL  Chimeric Transcription Factor∗  t(1;19)(q23;p13)  E2A‐PBX1 fusion  ~ 5 in BCP‐ ALL  Chimeric Transcription Factor t(9;22)(q34;q11)  BCR‐ABL fusion  ~ 5 in BCP‐ ALL  Activated Kinase dic(9;12)(p13;p13)  PAX5‐TEL (ETV6) fusion  ~ 1 in BCP‐ ALL  ? ∗   





PAX5 was recently shown to be the most frequent target of somatic mutation in BCP‐ALL. Mono‐allelic deletions, cryptic translocations or point mutations of Pax5 were detected in about 30% of BCP‐ALL cases examined (Mullighan et al., 2007). PAX5‐ETV6  fusion  defines most  of  the  cases with  dic(9;12)(p13;p13).  It  is  a  recurrent chromosome  abnormality  that  accounts  for  ~1%  of  childhood  ALL,  almost  exclusively BCP‐ALL (Strehl et al., 2003; Fazio et al., 2008).   This fusion product was first described 8 years ago. Until today not much is known about the molecular or cellular functions of the resulting fusion product. It is known that this  translocation  results  in  a  most  frequently  dicentric  fusion  of  the  N‐terminal  DNA binding  paired  box  domain  of  Pax5  on  chromosome  9  to  the  almost  full  sequence  of ETV6/TEL gene on chromosome 12 (Cazzaniga et al., 2001). In this fusion, ETV6 retains all  of  its  DNA  or  protein  interacting  domains,  HLH  (SAM/pointed)  and  Ets.  The combination  of  the  mentioned  facts  and  the  physiological  roles  of  the  genes  involved, leads  to  the  assumption  that  the  PAX5‐ETV6  fusion  protein  could  act  as  an  aberrant transcription factor, retaining the DNA binding domain of PAX5 and both the dimerization and DNA  binding  domains  of  ETV6.  Ten  years  ago  ETV6 was  shown  to  act  as  a  potent transcriptional  repressor  (Lopez  et  al.  1999).  Recently  (2008),  the  group  of  Giovanni Cazzaniga was the first to publish an in vitro transient transfection study investigating the oncogenic role of PAX5‐ETV6 fusion protein.  Indeed, they were able to show that PAX5‐ETV6 is a nuclear protein thus supporting the possibility of it being a transcription factor. They  were  also  able  to  show  the  specific  interaction  of  PAX5‐ETV6  and  mSin3A corepressor  complex.  The  regulatory  domains  of  ETV6  are  known  to  recruit transcriptional  cofactors  such  as  mSin3A,  NCoR  and  HDAC3  leading  to  transcriptional repression of  its  target genes  (Chakrabarti  et  al.,  1999; Guidez et  al.,  2000; Wang et  al., 2001).  Since  Pax5  inhibitory  and  activator  domains  are  lost,  it  would make  sense  that PAX5‐ETV6  is guided by  the actions of  the untouched regulatory domains of ETV6. The DNA binding paired domain of PAX5 which  is  left  intact during the  fusion might still be able to bind its targets, which would mean the deregulation of PAX5 target genes by ETV6. At  this  point,  all  BCP‐ALL  cases  analyzed  have  shown  only  a monoallelic  loss  of  PAX5, indicating  a  haploinsufficiency  or  the  generation  of  hypomorphic  alleles.  However,  this 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does not explain leukemogenesis, as B cell development is normal in heterozygous Pax5+/­ mice  (Urbanek  et  al.,  1994;  Nutt  et  al.,  1999).  Therefore,  the  PAX5  fusion  proteins  are thought to contribute to BCP‐ALL formation by interfering with the function of the Pax5 wild‐type allele (Cobaleda et al., 2007). The group of G. Cazzaniga was able to support this hypothesis  in  vitro  by  showing  that  PAX5‐ETV6  was  able  to  interfere  with  the transactivaton  function  of  wild‐type  Pax5  in  transient  transfection  assays  (Fazio  et  al. 2008).  Therefore,  the  possibility  prevails,  that  the  PAX5‐ETV6  fusion  protein  could contribute to BCP‐ALL formation by acting as constitutive repressor to antagonize PAX5 activity, which is  provided by the second, wild‐type Pax5 allele.    The Pax5 gene contains a potent B‐cell specific enhancer in the 5’ part of the large intron 5 (Decker et al., 2008). Interestingly, breakpoints of all previously mentioned Pax5 fusion  proteins  (Table  1),  except  for  PAX5‐ETV6  lie  downstream  of  this  enhancer.  The breakpoints of PAX5‐ETV6 translocation lie  in the intron 4 of Pax5 and intron 2 of Etv6. Importantly,  recent  chromatin  profiling  has  revealed  a  putative  enhancer  in  the  3’ sequences of the Etv6 intron 2, which likely directs transcription of the Pax5/Etv6 fusion gene  in  BCP‐ALL  in  the  absence  of  the  Pax5  enhancer  (McManus  S.,  Busslinger  M., unpublished data). 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1.9  Aim of the thesis project 
Most current treatments of childhood ALL are biologically crude and, although effective, are  associated  with  considerable  toxicity  and  morbidity  (Greaves,  Wiemels,  2003). Clearly,  there  is a need  for  further  improvements  in  treatment, preferably based on  the biological features of the disease. It  is widely anticipated that the next major advance in the treatment of ALL will  involve the use of designer therapies developed to specifically interfere with particular molecular abnormalities producing the leukemogenic aberration to the normal signal transduction pathways.  The  dicentric  translocation  dic(9;12)(p13;p13)  was  first  described  more  than    two decades ago  (Carroll et al., 1987),  it was  identified as a Pax5­Etv6  translocation 8 years ago  (Cazzaniga  et  al.,  2001).  Still,  the  molecular  and  cellular  effects  of  this  particular translocation,  responsible  for 1% of all  childhood BCP‐ALL cases,  stay  largely unknown (Strehl et al., 2003; Fazio et al., 2008). The elucidation of  these questions  is often made difficult by  the following facts. The Pax5­Etv6  translocation is not a very frequent event therefore little primary tumor tissue can be made available for analysis. There is usually enough  material  for  the  identification  of  the  responsible  translocation,  but  not  for allowing a systemic investigation of  its molecular effects. Furthermore, the malignant B‐lymphocytes cannot be cultured in vitro and thus no established cell lines are available for analysis.  The  aim  of  the  project  to  be  described  was  the  reconstruction  of  the  Pax5­Etv6 translocation by generating a conditional knock‐in allele in the mouse (Mus musculus).  The conditional activation of Pax5­Etv6 translocation allele with a B‐cell‐specific Cre  line will, for the first time, enable the investigation of the following questions:   1.) Upon  short  activation,  does  the Pax5­Etv6  translocation  allele  interfere with the normal B‐cell development? 2.) Which pathways and/or molecular functions of the wild‐type Pax5 protein are affected by this fusion product? 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3.) Does  this  translocation  perturb  the  B‐cell  regulatory  network  by  interfering  with the function of other relevant transcription factors? 4.) Upon long‐term activation, will this translocation lead to the development of B cell‐specific  leukemia? 5.) Which  oncogenes  or  tumor  suppressor  genes  cooperate  with  PAX5‐ETV6 fusion product to accelerate the formation of a neoplastic disease?  We hope that the generation of this transgenic animal will help to answer some questions about  the  cellular  and  the  molecular  nature  of  acute  lymphoblastic  leukemia  and therefore  to  contribute  on  the  long  run  to more  precise  and  effective  treatment  of  the affected children. 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2 Approach and Results 
Generation of a knock‐in mouse requires several well‐planned,  sequential  steps. First  is the generation of the desired allele in the form of a targeting vector. This step is routinely accomplished  by  cloning  and/or  recombeneering  methods  in  the  bacterial  organism 
E.coli.  Second,  the  isolated  DNA  of  the  targeting  cassette  has  to  be  brought  into  the genome of the embryonic stem cells of the mouse (mESCs). The rare event of homologous recombination has to be successfully identified by PCR and Southern Blotting techniques before the mESCs can be prepared for injection into mouse blastocysts. Finally, pups born have to be inspected for the degree of their chimerism, which is estimated from their fur color. High degree of chimerism means higher probability  for  the  following crossings to result in offspring with germline transmission of the targeted allele.  
2.1 Generation of conditional Pax5 knock‐in alleles 
2.1.1 Strategy 
A  targeting  vector  can have multiple  functions, which  allow  the  introduction  of  genetic alterations  into  the  genes  of  interest  by  homologous  recombination  in  the  embryonic stem (ES) cells of the mouse. The following is a general strategy outline for the generation of the Pax5­Etv6 targeting vector (Figure 8). A  loxP site was inserted into intron 3, and a stop codon at the end of the paired domain (Prd) in exon 4 of Pax5. A transcription stop cassette (six SV40 polyA sites) and a second 










exon 4 of Pax5. The control vector was used as a positive control for the nested PCR.   Our  targeting  vector  also  carries  genes  for  positive  and  negative  selection.  Positive selection was used to propagate only  those mESCs  in which homologous recombination had  occurred.  For  this  purpose  we  used  the  neomycin  gene  under  the  control  of  the eukaryotic phosphoglycerate kinase promoter (PGK‐neo), which renders cells resistant to neomycin/G418.  The  selection  gene  was  flanked  by  Frt  sites,  which  allowed  its subsequent deletion by Flp recombinase.    Negative  selection  was  used  to  kill  the  cells,  in  which  random  integration  had occurred instead of homologous recombination. Therefore the DT­A (diphtheria toxin A) gene was present outside the homology regions and could thus only be inserted into the genome by random integration, leading to the expression of the lethal toxin.    Another  important  feature of  the described strategy  is the future possibility to generate additional  Pax5  translocation  alleles  by  cDNA  replacement.  This  would  allow  the elucidation  of  the  functions  of  some  other  Pax5  fusion  products  such  as  Pax5‐Foxp1, 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Pax5‐Znf521 and Pax5‐ELN. All of them are thought to somehow interfere with the wild type  Pax5  function  and  consequently  with  B  cell  development.  The  sequences  of  the mentioned  fusion partner  genes  are  similar  to ETV6  in  that  they  also provide  a  second DNA  binding  domain  and  therefore  could  bind  their  target  genes  not  only  through  the paired domain of Pax5 but also  through their very own binding domains. All of the above mentioned  fusion proteins were shown  to  interfere with  the  transactivation  function of the wild type Pax5 in transiently transfected cells (Bousquet et al., 2007; Mullighan et al., 2007; Kawamata et al., 2008),  this  is an  indication  for a similar  function of  these  fusion proteins and is a good reason for further investigation of their function in vivo. The unique restriction sites BspEI and KpnI upstream of the biotin tag will allow the replacement of the Pax5­Etv6 sequence with  the corresponding Pax5­Foxp1, Pax5­Znf521 and Pax5­ELN cDNA sequences (Figure 10).   
  
Figure 10. The presence of unique BspEI and KpnI  restriction  sites allows  the generation of additional Pax5 
translocation alleles by cDNA replacement. Image courtesy of M. Busslinger   
2.1.2 Stepwise cloning of Pax5‐Etv6 targeting vector 
The Pax5­Etv6 targeting vector was cloned from scratch. Therefore, a polylinker with the necessary  restriction  sites  had  to  be  constructed  first.  The multiple  cloning  site  (MSC), carrying  the  following  restriction  sites:  NotI,  SalI,  NdeI,  BsiWI,  BspEI,  KpnI,  AscI,  PmeI, SacI,  PacI,  was  subsequently  inserted  into  a  DT‐A  containing  retrieval  plasmid.  This plasmid was going to be used for all the following successive cloning steps (Figure 11). 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Figure  11.    Detailed  representation  of    the  stepwise  construction  of  the  Pax5­Etv6  targeting  and  control 
vectors. First a  self­constructed polylinker / multiple  cloning  site was  inserted  into a DT­A carrying plasmid 
pBV­DTA­pA.  Then  two  independent  constructs  were  generated  carrying  the  neomycin  resistance  gene  and 
homology arms of  different lengths. A separately cloned fusion construct was then inserted into the homology 
arm constructs generating a targeting vector with a long and a short homology arm and a control vector for 
nested PCR carrying two long arms of homology for Pax5.   The  next  step was  the  generation  of  two  very  similar  constructs  both  of  which would carry the long homology arm and the neomycin resistance cassette under control of a PGK promoter. Second homology arms differed  in their  lengths,  the short one being used for the real targeting vector whereas the construct with the second long homology arm was used as a control vector for testing the nested PCR analysis.   The  first  gene  to  be  inserted  into  the  polylinker  was  the  PGK‐neo.  During  the  cloning process  a  mutation  in  the  DNA  sequence  of  neomycin  was  discovered.  The  neomycin resistance gene, originally derived  from transposon Tn5, encodes  the enzyme neomycin 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phosphotransferase  II,  which  confers  resistance  to  various  aminoglycoside  antibiotics, including  kanamycin  and  G418.  The  mutation  involved  a  glutamic  to  aspartic  acid convertion  at  residue  182  of  the  chimeric  gene,  which  was  previously  reported  to substantially  reduce  phosphotransferase  activity,  without  affecting  the  stability  of  the neomycin  phosphotransferase  II  mRNA  or  protein  (Yenofsky  et  al.  1990).  We  had  to repair the neomycin resistance cassette and then subclone it into the polylinker‐carrying plasmid.   The  homology  arms  were  obtained  by  recombeneering  also  known  as recombination mediated  genetic  engineering  in E.coli  and  subsequently  cloned  into  the previously mentioned DT‐A plasmid.  In parallel to the cloning of the two different homology arm/neo resistance constructs, a fusion construct was being cloned (top of Figure 11). The fusion construct consists of six pieces, which had to be cloned in six subsequent steps in a separate plasmid, then cut out with  the  restriction  endonucleases  SalI  and  AscI  and  inserted  into  the  homology  arm constructs creating the complete targeting and control vectors. This was the most efficient strategy  due  to  the  restrictions  given  by  the  enzyme  restriction  sites  available  in  the polylinker sequence.   Many of the fragments used for cloning and recombeneering were obtained by PCR, some of  the  fragments were directly  cut  out  of  different  plasmids  already  carrying  the  genes necessary for our construct.   
2.2 ES cell targeting 
The DNA used for ES cell targeting was obtained by maxi preparations and a subsequent phenol/chlorophorm extraction. After a  round of ES  cell work practice with  feeder‐free CCE ES cells (cell line derived from 129/Sv mouse strain), feeder‐dependent A9 mES cells were  targeted.  A9  mES  cells  are  dependent  on  mouse  embryonic  fibroblasts  (MEFs) derived  from the DR4 mouse strain (Tucker et al. 1997). The  feeder  layer  is resistant  to neomycin/G418,  6‐thioguanine,  puromycin  and  hygromycin,  and  survives  the  selection stress during the targeting process. 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A9  ES  cells  were  targeted  twice  with  the  vector  Pax5­Etv6­BIO  as  well  as  the  control vector.  352 Pax5­Etv6­BIO clones and 32 controls were picked.   
2.2.1 Screening for positive clones by nested PCR  



















2.2.2.1 Strategy All  four  positive  clones were  expanded  for  genomic  DNA  preparation  for  the  southern blot. Four ES cell clones obtained with control vector were chosen for expansion to test whether  some of  those had undergone homologous  recombination as well. The  second, longer homologous arm might have been an advantage in that case.  The Southern blot strategy was accordingly designed (Figure 14). The radioactive probe is  complementary  to  the  sequence  of Pax5  intron  4  and  hybridizes with  both  the  long homology arm as well  as  an external, non‐vector genomic  sequence. Digestion with  the restriction enzyme BglI yields a 7872 base pair  fragment  from the wild type Pax5 allele and a 4731 base pair fragment from the Pax5­Etv6­Bio fusion allele. 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Figure  14.  Southern  blot  strategy.  The  radioactive  1021  base  pair  3’  probe  anneals  to  the  sequence  at  the 
boundary of the long homology arm and the genomic intron 4 sequence of Pax5. The digest with BglI results in 
a 7.8 kb fragment of the wild type allele and a 4.7 kb fragment of the knock in allele.  














Germline  transmission  occurs  when  germ  cells  derived  from  the  injected  A9  cells  are passed on from the chimera to the next generation. The chimeras were crossed with FLPe deleter mice.  Southern  blot  analysis was  performed  to  prove  germline  transmission  as well as neomycin cassette deletion. Figure 17 portraits the Southern blot strategy used for the detection of neomycin cassette deletion. Figure 18 shows the proof for the successful germline transmission and neomycin cassette deletion. 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Figure  18.  A)  From  right  to  left  Southern  blot  analysis  of  two  of  the  eight  chimeras  confirming  the  correct 
integration of the knock­in allele. The remaining two lanes with a knock­in size band result from a crossing of a 
chimera  with  an  FLPe  mouse  (FLP  deleter  with  a  C57Bl/6  background).  The  knock  in  band  confirms  the 
germline transmission. B) Southern blot analysis of pups from another cross of a chimera and an FLPe. Five of 





Aim  of  thesis  project  was  the  generation  of  a  Pax5­Etv6  knock‐in  mouse,  which  was successfully  accomplished  in  a  time  span  of  one  year.  Germline  transmission  and neomycin cassette deletion were successful as well. A new and promising model organism was therefore made available for leukemia research.  From now on  the  new model  organism will  be monitored  and  thoroughly  analyzed  for short as well as long‐term effects of the knock‐in allele on B cell development.   Before the conditional activation of the knock‐in allele, the function of the Pax5Prd/+ allele alone  can be examined. Flow cytometry analysis of  the B  cell  compartment  in  the bone marrow  and  spleen  of  heterozygous  Pax5Prd/+  mice  will  determine  whether  the polypeptide resulting from the Pax5 paired domain alone can act as a dominant‐negative protein interfering with the function of the wild type Pax5 protein.  The hematopoietic‐specific Vav­cre line (de Boer et al., 2003) will subsequently be used to generate Pax5ETV6 allele in the Vav­cre Pax5Prd/+ mouse. The resulting Pax5ETV6/+ mice can then be compared to the Pax5Prd/+ mice. This should directly determine the additional B cell developmental defects contributed by the ETV6 sequence to the fusion protein.  In  order  to  gain  some  insight  of  the Pax5Prd/+ and Pax5ETV6/+  functions  at  the molecular level,  a  cDNA microarray  analysis  can  be  performed  to  determine  the  gene  expression pattern  of  the  pro‐B  cells.  This  can  be  subsequently  compared  to  the  already  available published data on the expression patterns of  the wild‐type as well as Pax5­/­ pro‐B cells (Delogu et al., 2006; Schebesta et al., 2007).  Pro‐B  cells  can  also  be  cultured  in  vitro.  The  biotinylation  of  Pax5‐Etv6  allows streptavidin‐mediated chromatin precipitation and subsequent Solexa sequencing of the precipitated  DNA  thus  leading  to  the  genome‐wide  identification  of  Pax5‐Etv6  target genes. In vitro cultured pro‐B cells of the Pax5ETV6/+ mouse, which also express the E.coli BirA ligase from the Rosa26BirA allele (Driegen et al., 2005), can be used for this purpose. 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This kind of a genome‐wide Pax5‐Etv6 target map can then be generated and compared to the available genome‐wide target map obtained from the pro‐B cell analysis of Pax5bio/bio Rosa26BirA/+ mice in M. Busslinger’s laboratory (IMP Vienna). The comparison of the wild‐type  Pax5  target  genes  with  the  target  genes  of  Pax5‐Etv6  will  reveal  the  alternative targets of the fusion protein as well as the usual targets, which might now be deregulated by the Pax5 fusion protein.  In  the  long  run,  it will  be  interesting  to  see whether Pax5ETV6/+ mice develop  leukemia. Tumorigenesis is a multistep process and usually, a single chromosomal translocation is not  sufficient  to  induce  leukemia.  Cooperating  oncogenic  lesions  might  be  necessary (Hanahan and Weinberg, 2000; Mullighan et al., 2007). Chromosomal aberrations thought to be exclusively associated with leukemias and lymphomas have been detected in normal individuals,  indicating  that  such  translocations  can  be  generated  without  apparent oncogenic  consequences  (Brassesco  et  al.,  2008).  Besides,  studies  with  ETV6­RUNX1 knock‐in mice have shown that the expression of this hybrid gene is not sufficient for the induction of ALL (Andreasson et al., 2001). Human BCP‐ALL cases characterized by PAX5 mutations  frequently contain additional heterozygous  Ikaros  (Ikzf1) mutations or ETV6­
RUNX1 translocations (Mullighan et al., 2007). Moreover, BCP‐ALL is often characterized by the deletion of CDKN2A  locus coding for the p16INK4A  inhibitor of cyclin D‐dependent kinases (Sulong et al., 2008). Therefore, it would make sense to cross the Pax5ETV6/+ mice with Ikzf1+/­ (Wang et al., 1996), Cdkn2a+/­ (Kamijo et al., 1997) or conditional Etv6­Runx1 knock‐in mice (in collaboration with Dr. H. Hock, Harvard Medical School, Boston) and see if tumors arise. If tumors arise, leukemic cells of these mice can be further characterized by analyzing their gene expression profile using cDNA microarray analysis. Direct targets of PAX5­ETV6 protein can then be identified by ChIP sequencing. Finally the expression of all newly identified and relevant genes can be compared to the available human BCP‐ALL samples (in collaboration with Dr. S. Strehl, Children’s Cancer Research Institute, Vienna).  Additionally, as described earlier, the cloning strategy of the Pax5‐ETV6 fusion envisions the quick generation of the fusion product Pax5‐Foxp1, Pax5‐Znf521 and Pax5‐Eln knock‐in  alleles  as  well.  As  soon  as  these  targeted  mice  become  available,  a  comparison  of 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Pax5ETV6/+, Pax5Foxp1/+, Pax5Znf521/+ and Pax5Eln/+ mice could reveal whether all four fusion‐proteins interfere with B cell development in similar or different ways.   To summarize, PAX5 has been shown to be the target of somatic mutation in about 30% of pediatric ALL cases. The identified mutations resulted in reduced levels of PAX5 protein or the generation of hypomorphic alleles (Mullighan et al., 2007).  In childhood BCP‐ALL 





4.1.1.1 Plasmid DNA mini­preparation  Minipreparation  of  plasmid  DNA  is  a  rapid,  small‐scale  isolation  of  plasmid  DNA  from bacteria.  It  is  based on  the alkaline  lysis method  invented by  the  researchers Birnboim and Doly in 1979. When  bacteria  are  lysed  under  alkaline  conditions  both  DNA  and  proteins  are precipitated. After  the addition of acetate‐containing neutralization buffer  the  large and less supercoiled chromosomal DNA and proteins precipitate, but the small bacterial DNA plasmids can stay in solution. Minipreparation of plasmid DNA was used for the preparation of up to 20 µg of high‐copy plasmid  DNA  from  cultures  of  Escherichia  coli  using  the  QIAprep®  miniprep  kit  from Qiagen. A single colony was picked from a freshly streaked selective plate and a culture of 1–5 ml  LB  (Luria‐Bertani)  medium  containing  the  appropriate  selective  antibiotic  was inoculated.  After  12–16  h  incubation  at  37°C  with  vigorous  shaking  plasmid  DNA was isolated according to the manufacturers protocol.  
4.1.1.2 Mini­preparation from BAC clones Qiagen QIAprep® buffers were used for the following procedure: 1. Inoculate a single, isolated bacterial colony in 3ml LB medium supplemented with 25µg/ml chloramphenicol. Use a 12‐15ml snap‐cap polypropylene tube.  Incubate at 37°C for 12‐16h with vigorous shaking.  2. Pellet cells by centrifugation at 3000 rpm for 10 min 3. Aspirate  supernatant.  Resuspend  the  pellet  in  0.3ml  of  buffer  P1 containing 100 
µg/ml RNase A (stored at 4°C).  4. Add 0.3ml of buffer P2 and mix gently.  Incubate at  room temperature  for 5 min. The appearance of the solution should change from turbid to almost translucent. 5. Slowly add buffer P3  to each  tube and gently shake. A  thick, white precipitate of 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protein and E.coli DNA will form. Incubate on ice for 5‐10 minutes. 6. Centrifuge the suspension at 10000 rpm for 10 min at 4°C. 7. Keep  on  ice  immediately  after  centrifugation.  Remove  supernatant  and  add  a microcentrifuge tube containing 0.8ml ice‐cold isopropanol. Mix well by inverting the tube few times and keep on ice for 5min. At this stage, if necessary samples can be frozen at ‐20°C o/n. 8. Spin at 4°C in a microcentrifuge for 15 min at 13000 rpm. 9. Carefully remove the supernatant and add 0.5ml of 70% ethanol to wash the pellet.  Centrifuge at 4°C for 5 min at 13000 rpm. Repeat this step if necessary. 10. Carefully aspirate the supernatant and let the pellet air‐dry at room temperature. Resuspend in 40µl TE buffer. Do not pipet to resuspend the pellet. Gently tap the tube at the bottom several times to resuspend the BAC DNA. For large PAC clones resuspension may take up to 1h. 
 
4.1.1.3 Plasmid DNA maxi­preparation  DNA maxi preparations were done using the Qiagen Plasmid Maxi Kit. A single colony was picked from a freshly streaked selective plate and a culture of 1–5 ml LB (Luria‐Bertani) medium  containing  the  appropriate  selective  antibiotic  was  inoculated.  After  6‐8  h incubation at 37°C with vigorous shaking the starter culture was diluted 1/500 to 1/1000 into  selective LB medium.  It was  subsequently grow at 37°C  for 12–16 h with vigorous shaking (approx. 300 rpm). The bacterial cells were harvested by centrifugation at 6000 x g  for  15  min  at  4°C.  The  following  DNA  maxi  preparation  was  done  according  to  the manufacturers protocol. The protocol used was designed for preparation of up to 100μg of high‐ or low‐copy plasmid DNA . 
 
4.1.1.4 DNA extraction from agarose gels Gel electrophoresis was used as a preparative technique to separate DNA according to its size  prior  to  cloning.  Low‐melting  Seaplaque  Agarose  gels  in  TAE  buffer  were  used. Ethidium Bromide was added to the gel as  intercalating agent  for staining nucleic acids. DNA bands were visualized in UV‐light (366nm) and excised with a scalpel. QIAquick Gel Extraction Kit  from Qiagen was used  fro  the DNA extraction  from the agarose gels. The procedure was performed according to the manufacturers protocol. 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4.1.1.5 DNA precipitation using Ethanol DNA  had  to  be  precipitated  during  cloning  between  double  digest  cloning  steps  with unmatching restriction endonuclease buffers.  Procedure 1. Add  0.03Vol  of  3M  NaAc  pH  5.2  and  2.5Vol  of  pure  Ethanol  to  the  cloning reaction‐mix and precipitate the DNA at ‐20°C for 20 minutes. 2. Spin for at 13000rpm for 10 min in a table‐top microcentrifuge. 3. Wash the pellet with 70% Ethanol 4. Re‐dissolve the pellet in sterile MonoQ water  5. Go  on  with  cloning    add  the  second  restriction  endonuclease  and  the matching buffer  
4.1.1.6 Plasmid DNA purification by phenol/chlorophorm extraction The targeting vector plasmid DNA obtained from a QIAGEN Plasmid Maxi preparation had to be linearized and Phenol/Chloroform purified before electroporation into ES cells. This  method  is  effectively  used  for  protein  removal  from  nucleic  acids.  Proteins precipitate at  the organic/aqueous  interphase  in  form of a white cloudy substance. The aqueous  phase  is  extracted  several  times  using  Phenol‐Chloroform‐Isoamylalcohol (25:24:1) mix until no more protein precipitates. The final chloroform extraction is used to remove phenol leftovers, which might still be dissolved in the aqueous phase.  Procedure 1. Linearize  the vector by digesting 100µg of  the maxiprep DNA for 4h with  the unique  cutter  (PvuI  or  SgrAI)  restriction  endonuclease  (0.5U/µg)  in  a  total volume of 40µl. 2. Fill  up  to  500µl  with  sterile  MonoQ  water  (use  safe  lock  eppendorf  microcentrifuge tubes ) 3. Add 1Vol of Phenol, shake and spin at 13000 rpm for 5 min at RT 4. Transfer aqueous phase into a fresh safe lock tube  5. Purify again with phenol 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6. Purify 2x with chloroform 7. Fill up to 500µl with sterile MonoQ water 8. Add 10% (50µl) 3M NaAC 9. Add 0,7 Vol (385µl) Isopropanol, shake gently, DNA precipitates. 10.  Spin at 13000 rpm for 15 min at RT 11.  Wash the pellet with 70% EtOH (500µl) 12.  Spin at 13000 rpm for 5 min at RT 13.  Air dry pellet and resuspend in 20µl TE Buffer pH 8.0 14.  Run 1µl of the purified and linearized DNA on 0.9% Agarose gel. 15.  Measure the DNA concentration, 10 ‐ 25µg of targeting vector are required for the electroporation into the ES cells.   
 
4.1.2 Measuring DNA concentrations 
The concentration and quality of sample DNA is measured with a UV spectrophotometer. A solution containing 50 µg/ml of double strand DNA (dsDNA) has an absorbancy (optical density) of 1.0 at a wavelength of 260 nm. 50/1.0 = (DNA)/OD read  (DNA) = 50 x OD read The essential amino acid tryptophan has a wavelength of maximum absorption of 280 nm and is used as an indicator for purity vs. protein contamination of the DNA sample. If the sample  is  contaminated,  additional OD will  be measured, which decreases  the OD  ratio between 260 and 280 nm. Clean DNA has an OD 260/280 ratio between 1.8 and 2.0. If the measured value is somewhat smaller, it indicates a contamination.  All  the  concentration  measurements  were  done  using  Nano  Drop  1000 spectrophotometer: 1. With  the  sample  apparatus  open,  a  droplet  of  sample  (1µl)  is  pipeted  onto  the measurement pedestal.  2. When  the  sample  apparatus  is  closed,  the  sample  arm  slightly  compresses  the droplet and a sample column is drawn. Surface tension alone holds the sample in place. The spectral measurement is then made and quantification is made based on the tightly controlled path length of 1mm. 3. When  the  measurement  is  complete,  the  sample  apparatus  is  opened  and  the 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sample  is simply wiped  from both  the sample arm and sample pedestal using an ordinary dry laboratory wipe. 
 
4.1.3 Agarose Gel Electrophoresis 














Incubate for 1h at 37°C Pool all reactions Incubate at 95°C for 5 min Cool down (This  is  included  in  the  PCR machine  Program  LINKER,  but  you  have  to  change  some conditions, I think Heat is on 70°C…)  STEP 2 Ligation into Vector DNA  Since the polylinker DNA concentration is pretty high, use very little insert DNA I did 3 ligations with decreasing insert concentrations 1μl, 0,5μl and 0,3μl, ­CNT  STEP 3 Transform into DH5α  
4.1.5.2 Recombeneering Recombineering  (recombination‐mediated genetic  engineering)  is  a  technique based on homologous  recombination  systems  mediated  by  bacteriophage  λ  proteins  in  E.Coli  to modify  DNA.  These  homologous  recombination  systems  mediate  the  efficient recombination of a  target  fragment  into  the DNA construct. The method makes use of a defective  λ  prophage  to  supply  functions  to  E.Coli  that  protect  and  recombine  the electroporated  linear DNA.  This  defective  prophage  carries  a  deletion  between  cro and 
bioA. The PL operon encoding gam and the red recombination genes, exo and bet, is under the  tight  control  of  the  temperature  sensitive  repressor  (allele  cI857).  Recombination functions can thus be transiently supplied by shifting the cultures to 42°C for 15 min. This recombination  system  does  not  require  RecA  function  and  depends  primarily  on  the expression of Exo, Beta, and Gam. Gam inhibits the E. coli RecBCD nuclease from attacking the electroporated linear DNA, while Exo and Beta generate recombination activity. The sequence homologies (or arms) flanking the desired modifications are homologous to regions 5' and 3' to the region to be modified. Importantly, the recombination is proficient with  DNA  homologies  as  short  as  30–50  bps,  making  it  possible  to  use  PCR‐amplified fragments as the targeting cassette. It  is  a  powerful  method  for  fast  and  efficient  construction  of  vectors  for  subsequent 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manipulation  of  the mouse  genome  or  for  use  in  cell  culture  experiments.  It  is  also  an efficient way of manipulating the bacterial genome directly.  
E.Coli  strain  EL  350 was  used  in  our  experiments.  These  bacteria  contain  a  defective  λ prophage  with  recombination  proteins  exo,  bet,  and  gam  being  controlled  by  the temperature‐sensitive  repressor  cI857.  EL350  also  contains  a  tightly  controlled arabinose‐inducible cre gene. cre will mediate recombination between two identical loxP sites.  Transfer of BAC DNA into EL 350 E.coli cells Procedure 1. Pick  a  single  colony  of  EL  350 E.coli  from  a  freshly  streaked  selective  plate  and inoculate a culture of 5ml LB (Luria‐Bertani) medium Incubate for 12–16 h at 30‐32°C with vigorous shaking. 2. Transfer 1 ml of this culture to 20 ml of fresh LB medium. 3. Incubate for ∼2h at 30‐32°C with vigorous shaking until the OD = 0.5. 4. To  make  the  cells  competent  work  on  ice  and  use  pre‐cooled  reagents  and instruments,  such  as  tubes,  pipettes,  etc.  Use  10ml  of  bacterial  culture  per preparation. 5. Incubate on ice for 5 min. 6. Pellet bacteria by centrifugation at 4000rpm for 5 min at 0°C. 7. Remove the supernatant and re‐suspend the pellet in 1ml of ice‐cold sterile water and transfer the cell suspension to pre‐cooled 1.5ml microcentrifuge tube. 8. Centrifuge the cell suspension for at 4000rpm for 5 min at 0°C. 9. Wash the pellet with ice‐cold sterile water, then with 15% ice‐cold glycerol. 10. Resuspend  the  pellet  in  50µl  of  15%  ice‐cold  glycerol  and  transfer  to electroporation cuvette (BioRad Gene Pulser cuvette, 0.2 cm). 11. Electroporate 1µl  (∼100ng) of BAC DNA using Bio Rad Gene Pulser  set  at 2.5kV, 25µF with the pulse controller set at 200Ω. 12. Add 1ml of LB medium to cells, incubate at 32°C for 1.5h with shaking and spread on chloramphenicol selective agar media.  Insertion of targeting cassette Procedure 1. Cut out the targeting cassette flanked by the homology boxes with the appropriate 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restriction enzymes from vector DNA and purify. 2. Pick a single colony of EL 350 E.coli containing the BAC of interest from a freshly streaked selective plate and inoculate a culture of 5ml medium Incubate for 12–16 h at 30‐32°C with vigorous shaking. 3. Transfer 1 ml of this culture to 20 ml of fresh selective LB medium and incubate at 30‐32°C for ∼2h with vigorous shaking until OD=0.5. 4. Transfer 10ml of the bacterial culture to a separate flask and incubate at 42°C for 15min with shaking to induce recombination enzymes. 5. Place the flask on ice immediately and incubate for 5min. To make cells competent follow steps 4‐10 from previous protocol (Transfer of BAC DNA into EL 350 E.coli cells). 6. Electroporate 1‐2µl of purified, linear targeting cassette DNA (same settings as in step 11 from previous protocol (Transfer of BAC DNA into EL 350 E.coli cells)). 7. Add 1ml of LB medium to cells, incubate at 32°C for 1.5h with shaking and spread on appropriate selective agar media. 
 
4.1.5.3 Molecular cloning of targeting vectors Ristriction  endonuclease  digestion,  ligation  and  heat  shock‐transformation  were  the standard techniques used for  the generation of  the targeting cassettes. DH5α  cells were used for all procedures. For the long‐term preservation of cells carrying cloned constructs Hogness buffer was used.  Hogness buffer for long term preservation of bacterial cells: 36mM K2HPO4 . 3H2O  13mM KH2PO4 20mM Na3‐Citrat . 2H2O  10mM MgSO4 . H2O 44% Glycerol  
4.1.5.4 Electroporation Electroporation  is  a  quick  and  stable  transfection  method,  used  to  deliver  DNA  for homologous  recombination  into  bacterial  or  animal  cells.  It  is  a  dynamic  phenomenon that depends on the  local  transmembrane voltage at each cell membrane point. The cell membrane permeability to ions and macromolecules is increased, by exposing the cell to 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short (microsecond to millisecond), high voltage electric field pulses.  It  is  generally  accepted  that  for  a  given  pulse  duration  and  shape,  a  specific transmembrane  voltage  threshold  exists  for  the  manifestation  of  the  electroporation phenomenon (from 0.5V to 1V). This leads to the definition of an electric field magnitude threshold for electroporation (Eth). That  is, only the cells within areas where E≧Eth are electroporated.  If  a  second  threshold  is  reached  or  surpassed,  electroporation  will compromise the viability of the cells and result in irreversible electroporation. High DNA concentrations will  increase  transfection efficiency.   Highly compromised cell viability leads to high electroporation efficiencies.  Electroporation was used for recombineering in E.coli cells as well as for targeting mouse (mus musculus) Embryonic Stem (ES) cells.  
4.2 mES cell Culture 
4.2.1 General principles 
The  culture  of mES  cells,  whilst  not  difficult,  is  a  labour‐intesive  process  that  requires considerable care and attention to detail. Although mES cells may continue to proliferate under suboptimal conditions, they readily lose their ability to contribute to chimeras and be  transmitted  through  the  germline.  Hence  it  is  vitally  important  to maintain  optimal culture conditions at all times. All  used  reagents  were  tissue‐culture  grade,  and  solutions made  up  with Mono‐Q  or Milli‐Q  water.  Disposable  plastics  were  used  wherever  applicable.  Rigorous  aseptic technique was maintained. All cell cultures were maintained in a humidified incubator, gassed with 5% CO2 in air, at 37°C. The  quality  of  the  fetal‐calf  serum  (FCS)  in  the  culture  medium  is  a  critical  factor determining the success of mES‐cell derivation. Sera vary considerably between batches in their ability to support the proliferation of pluripotent mES cells in the undifferentiated state, and it is therefore crucial to test a range of samples and select only the best for mES cell culture. An FCS previously successfully tested on ES cells in our laboratory was used. Established mES cell lines divide rapidly and are maintained at a relatively high density, and therefore require regular maintenance: the medium was changed daily to prevent its acidification, and the cells passaged approximately every 2‐3 days. 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More efficient germline transition is achieved when targeted cells in addition to being co‐cultured with  feeder  cells,  are maintained  in  a medium  containing  leukemia  inhibitory factor (LIF).  
4.2.2 Mycoplasma contamination 
Contamination with mycoplasma can be highly problematical for mES cell culture, being readily  apparent  neither  macroscopically  nor  microscopically,  and  having  calamitous consequences  for  the  pluripotency  of  mES  cells.  Crucially,  blastocyst  injection  of mycoplasma‐contamined  mES  cell  lines  results  in  embryo  lethality,  and  a  dramatic reduction  in  the  numbers  of  chimeras  obtained  as  well  as  the  level  of  mES  cell contribution  to  their  tissues.  Elimination  of  mycoplasma  contamination  is  impractical, treatment with  antimycoplasma  agents  being  detrimental  to mES  cells.  Therefore  once mycoplasma is detected in either mES cells or feeder cells, the best course of action is to discard  the  cutures.  The  most  common  sources  of  mycoplasma  infection  are  other contamined cultures, sera, or laboratory personnel using poor aseptic technique.   
4.2.3 Tissue culture Equipment  
1. Water bath set at 37°C 2. Differently  sized  sterile  tissue‐culture  dishes  and  flasks  (e.g.  96,  24,  12,  6  well dishes, Nunclon). 3. Polystyrene pipets (25ml, 10ml, 5ml, 2ml, 1ml) 4. Filtered pipet tips (e.g. from Molecular Bio Products) 5. Sterile Falcon tubes (15ml, 50ml, Falcon) 6. Cryovials (1ml, Nunc) 7. 70% Alcohol 8. Phosphate‐buffered saline (PBS) without Ca2+ or Mg2+  9. High Glucose Dulbecco’s modified Eagle’s medium (DMEM)  10. Fetal‐calf serum (FCS): this must be tested for optimal ability to support mES cell culture, aliquot into 50ml and store at ‐20°C (Batch No. … Sigma) 11. β‐mercaptoethanol  stock  solution  (100x  ):  Add  35.7µl    to  50ml  of  PBS.  Filter sterilize, aliquot 5ml per tube and store at ‐20°C 12. Penicillin (Cat. No. P4687 Sigma) 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13. Streptomycin (Cat. No. S1277 Sigma) 14. Glutamine, 200mM (Cat. No. G7513 Sigma) 15. Murine recombinant LIF (ESGRO®; Cat. No. ESG 1106, Chemicon International) 16. MEM non‐essential amino acids, 100x solution (Cat. No. M7145 Sigma) 17. Na‐Pyruvate 18. Trypsin  solution:  make  5ml  aliquots  from  the  10x  stock  solution  and  freeze immediately  to  maintain  maximum  activity.  Always  thaw  a  fresh  aliquot  before use. 19. Geneticin /G418 20. ESGRO LIF (Leukemia inhibitory factor) 21.  DMSO (Dimethyl sulfoxide, Sigma)  
4.2.4 Tissue culture reagents 
4.2.4.1 MEF culture medium Combine the following constituents: 1. 450ml High glucose DMEM 2. 50ml FCS 3. 10ml PSG (Penicillin Streptomycin Glutamine premade aliquot)  
4.2.4.2 MEF freezing medium Prepare fresh before use Combine the following constituents: 1. 50% FCS 2. 40% MEF culture medium 3. 10% DMSO  
4.2.4.3 mES cell culture medium 1. 450ml High glucose DMEM 2. 5ml  β‐mercaptoethanol aliquot 3. 5ml Na‐Pyruvate aliquot 4. 5ml aliquoted Non‐essential amino acids 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5. 10ml PSG (Penicillin Streptomycin Glutamine premade aliquot)  
4.2.4.4 FCS/LIF medium mES cell medium For full FCS/LIF medium combine: 1. 85ml mES cell culture medium (premade) 2. 15ml FCS 3. 10µl ESGRO LIF (1000U/ml) mES cell medium containing FCS and LIF has to be made fresh every second day. 
 
4.2.4.5 G418 selection medium For G418 selection medium combine: 1. 99ml full mES cell medium with FCS /LIF 2. 1ml of a 100X G418 stock solution (e.g. to make a 100x stock solution take 300mg of active geneticin (418mg of 716µg/mg active geneticin) and dissolve  it  in 10ml full mES cell medium) 
 
4.2.4.6 mES cell freezing medium Prepare fresh before use Combine the following constituents: 1. 50% FCS 2. 40% full mES cell culture medium 3. 10% DMSO  
4.2.5 Preparation of MEFs 
ES cells were always cultured on irradiated, mitotically inactivated feeder layer of mouse embryonic fibroblasts (DR4 pMEF). MEFs  proliferate  for  only  a  limited  period  in  culture;  new  stocks  have  to  be  prepared regularly.  Aliquots  may  be  cryopreserved,  and  so  fresh  stocks  need  only  be  prepared every few months. Feeder cells must be mitotically inactivated to prevent their proliferation and consequent overgrowth of the mES cell culture. This can be achieved using e.g. γ‐irradiation. 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4.2.5.1 Expansion and gamma (γ) ­ irradiation. 1. Rapidly thaw a frozen aliquot of MEFs by holding the vial momentarily in a water bath  set  at  37°C;  thoroughly  swab  the  outside  of  the  vial with 70% alcohol,  and transfer the contents to a centrifuge tube containing 10ml MEF medium. 2. Pellet  the  cells  in  a  benchtop  centrifuge  at  1500rpm  for  5  min.  Aspirate  the supernatant, and gently resuspend the cell pellet in 2ml MEF medium. Add the cell suspension to 23ml MEF medium in a 140cm2 cell culture dish and incubate. 3. Change  the medium the  following day only;  there  is no need  for  further medium change  between  passages.  The  dish  should  reach  confluence  on  the  second  day after incubation. MEFs can be subcultured three or four times from this stage (i.e. to  passage  5  or  6)  at  a  split  ratio  of  1:3,  following  which  they  usually  cease  to proliferate.  4. To γ‐irradiate  the MEFs add 2ml of 1 x  trypsin  solution  to  the  confluent 140cm2 cell culture dishes and incubate at 37°C for 4‐5 min. Rock the plate until the cells detach, add 5ml MEF medium, pipet up and down to give a single cell suspension and collect the detached cells in 50ml sterile Falcon tubes with MEF medium. 5. Place the Falcon tubes inside a 60Co source, and γ‐irradiate the cell suspension with 3000rads.  6. Pellet  the  cells  in  a  benchtop  centrifuge  at  1500rpm  for  5  min.  Aspirate  the supernatant,  and  gently  resuspend  the  cell  pellet  in  0.5ml  MEF  medium  per 140cm2 cell culture dish. 7. Transfer 0.5ml aliquots of cell suspension into cryovials containing 0.5ml freezing medium,  mix  gently  and  freeze  slowly  at  ‐70°C,  before  storing  under  liquid nitrogen. 8. After thawing one 0.5 MEF aliquot is sufficient to seed a 140cm2 cell culture dish. Place the vial in a 37°C water bath thaw quickly, swab with 70% alcohol and follow the protocol from steps 1 and 2. 
 
4.2.6 Mouse embryonic stem cell targeting 
A9 mES cells were used for targeting.  Feeder  cells were  always  plated  one  day  before  or  at  least  3  hours  prior  to  ES  cells  to allow attachment to the tissue culture dish. 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4.2.6.1 Expansion DAY 1 Take ES cells with a  low passage number and rapidly  thaw the  frozen aliquot by holding the vial momentarily in a water bath set at 37°C; swab the outside of the vial with 70% alcohol  and  transfer  the  contents  to  a  centrifuge  tube  containing 10ml  full  ES  cell medium.  Pellet  the  cells  in  a  benchtop  centrifuge  at  1000rpm  for  5  min.  Aspirate  the supernatant and gently resuspend the cell pellet in 1ml full ES cell medium. Aspirate and replace the MEF medium on the 140cm2 dish with 20 ml full ES cell medium. Add the ES cell suspension to the full ES cell medium on the 140cm2 tissue culture dish and incubate. DAY 2 Change mES cell  culture medium by  carefully  aspirating  the old  culture medium from the plate and slowly adding fresh medium to one side of the plate without disturbing the cells. DAY 3 Passage  the ES  cells  in  ratio  of  1:8,  keep  two 140cm2  tissue  culture  dishes  (one plate per targeting vector/control vector electroporation)  Note: Wash cells  twice with PBS. Trypsinize by adding 2ml  trypsin solution to  the plate and incubating for 5 min at 37°C. Halt trypsinization by adding 1ml of mES cell medium. It is essential at this point to dissociate colonies into single mES cells, which is achieved by pipeting  the cell  suspension up and down. Monitor  the progress of dissociation under a microscope and once a single cell suspension is obtained, transfer this into a sterile tube with  mES  cell  medium,  pellet  the  cells  by  centrifugation,  aspirate  the  supernatant, resuspend the pellet in 8ml of mES cell medium and add 1ml to a 140cm2 dish (previously covered with MEFs) with 20 ml full ES cell medium. DAY 4 Change mES cell culture medium (FCS/LIF) 
 
4.2.6.2 Electroporation DAY 5 Electroporation  Procedure 1. Detach  the  cells  by  trypsinization  (make  sure  it  is  a  single  cell  suspension)  and pellet by centrifugation. Dissolve cells (10 x 106) in 0.8ml PBS (Phosphate Buffered Saline) 2. Add  15‐25µg  of  purified  targeting  vector/control  vector  DNA  to  the  cell suspension and mix well 3. Transfer  the  suspension  to  electroporation  cuvette  (BioRad Gene Pulser  cuvette, 0.4cm) 4. Electroporate using Bio Rad electroporator  at 0.24kV, 500F. White  foam of dead 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cells  will  form  on  the  top  of  the  cell  suspension  indicating  successful electroporation. 5. Leave the cells in the cuvette; let them rest for 10min at room temperature in the sterile hood. 6. Transfer the electroporated cells into full ES cell medium, mix well and split to cell culture plates.  (Split 1:4, keep  four 56cm2 plates  for ES cells electroporated with targeting vector and one plate for cells carrying the control vector) DAY6 Change ES cell culture medium (FCS/LIF)             36 hours post electroporation Start selection with G418 containing mES              cell selection medium. Change selection medium every day. 
 
4.2.6.3 Picking Pick mES cell clones 5‐7 days post electroporation.  Whether  the colonies are ready to be picked has  to be assessed on  individual basis and depends on the ongoing stage of selection with G418, as well as the size and density of the colonies. Procedure: Prepare a 96 well cell culture dish by plating feeder cells in MEF medium at least 3 hours prior  to  picking.  Exchange  the  MEF  feeder  medium  with  200µl  full  mES  cell  medium immediately  before  picking.  Only  ideal  colonies  should  be  picked.  Colonies  should  be slightly  smaller  than  the  end of  a  20µl  pipette  tip.  Edges  should be  clearly  defined  and there should be no cells flattening or differentiating along the outside edges. 1. Wash the 140cm2 cell culture dish containing targeted mES cell colonies twice with PBS, carefully aspirate and add 10ml PBS to the dish. 2. Pick clones in 20µl PBS by detaching from the plate with the pipette tip aspirating in  one  motion.  Place  the  clones  into  a  96  well  PCR  plate.  This  should  be  done quickly; cells should not be without medium for much longer than 30 min. 3. Add 20µl of 2x trypsin solution to each well and incubate at 37°C for 5min. 4. Pipet up and down in order to obtain a single cell suspension, transfer 20µl to the 96‐well plate with feeders and incubate. 5. Add 100µl PBS to the cell suspension left on the PCR plate and continue picking the next plate. 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4.2.6.4 Nested PCR Primers used: Forward: MB 9559/MB9560; Reverse: MB9561/MB9562 DNA was prepared for PCR: 1. Spin the 96 well PCR plates in a bench‐top centrifuge for 5min at 1500rpm. 2. Remove supernatant. 3. Add 10µl Proteinase K solution (1mg/ml) to each well and incubate for 1h at 55°C in a heated PCR block. 4. Add 50µl of  sterile Water  to each well and  inactivate Proteinase K by  incubating for 10min at 95°C   2µl DNA of ES cell genomic DNA was used for the reaction, controls were included. Optimized Program was used: 94°C: 5min 94°C: 30sec 55.2°C: 30sec 72°C: 3min 15sec 72°C: 5min 10°C: Forever  PCR product was run on agarose gel. Positive clones were expanded and aliquots frozen to obtain enough DNA for a southern blot.  
4.2.7 Southern Blot Analysis  




4.2.7.2 Proteinase K digestion and DNA preparation for Southern Blot 1. Expand  the  PCR‐positive  mES  cell  clones  by  passaging  the  cells  every  2‐3  days from a 96‐well plate to a 24, 12, 6‐well and finally a 140cm2 plate and let grow for approximately one week. 2. Wash the cells twice with PBS, add 2ml trypsin solution and incubate for 5 min at 37°C. 3. Collect the cells with a pipette and add to a 15ml Falcon tube containing 5ml mES cell medium.  4. Pellet the cells by centrifugation at 1500 rpm for 5 min. 5. Aspirate  the  supernatant  and dissolve  the pellet  in 4.5ml 1x Proteinase K buffer (without SDS). 6. Add  300µl  Proteinase  K  (stock  solution:  20mg/ml,  final  concentration:  1mg/ml) and mix well. 7. To  lyse  the  cells  quickly  add  250µl  of  20%  SDS  (final  concentration  1%  SDS) solution. 8. Incubate at 55°C over night. 9. Next day add 200µl of 5M NaCl (0.3M NaCl final concentration). 10. Extract 2x with 1 Volume (5ml) of Phenol, spin for 5min at 4000rpm (4°C) 11. Extract 2x with 1 Volume (5ml) of Chloroform, spin for 5min at 4000rpm (4°C) 12. Remove the aqueous phase and fill it up to the volume of 5ml with sterile water 13. Add 3 Vol. (15ml) of Ethanol, shake gently and DNA will precipitate. 14. Fish  the DNA with a Pasteur pipette  tip, wash with 70% Ethanol and dissolve  in 400µl preheated TE buffer (65°C). 15. Measure the DNA concentration. 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4.2.7.3 DNA digestion and separation DAY 1  30U  of  Restriction  endonuclease  BglI  was  used  to  digest  15‐20  µg  of  genomic  DNA prepared from ES cells in a volume of 50 µl.  DAY2 10U of restriction enzyme were added for 2 more hours. The DNA fragments were then run on 0,9% agarose gel in 0,5 X TAE buffer for 6 hours at 130V and subsequently photographed with a fluorescent ruler. Prior to blotting the gel was 
• Depurinated  for  15  min  in  500ml  of  diluted  HCl  acid,  breaking  the  large  DNA pieces  into smaller ones  in order  to allow more efficient  transfer  from the gel  to the membrane. 





  Whatman®  paper  and  the nylon membrane  are  soaked  in 20  x  SSC prior  to blotting. A 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sheet of nylon membrane is placed on top of the agarose gel. Pressure is applied evenly to the gel (by placing a stack of paper towels and a weight on top of the membrane and gel), to ensure good and even contact between gel and membrane. Buffer transfer by capillary action from a region of high water potential to a region of low water potential is then used to move  the DNA  from  the gel on  to  the membrane.  Ion exchange  interactions bind  the DNA to the membrane due to the negative charge of the DNA and positive charge of the membrane. 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